Vineet Laboratories Announces Board Changes and Reports Q2 FY2026 Results

Vineet Laboratories Limited , a player in the Active Pharmaceutical Ingredients (API) and Intermediates sector, has announced significant changes to its board composition along with its financial results for the second quarter of fiscal year 2026.

Board Changes

The company has made several key changes to its board structure:

New Independent Director: Ms. Jasmin Kunal Tailor has been appointed as an Additional Non-Executive Independent Director for a three-year term, effective from November 9, 2025, to November 8, 2028. This appointment is subject to shareholder approval.
Director Resignation: Ms. Hari Priya Yerukalapudi has resigned from her position as Independent Director, effective November 8, 2025, citing changes in professional priorities and family necessities.
Remuneration Revisions: The board has approved revised remuneration packages for Mr. Gaddam Venkata Ramana, Managing Director, and Mr. Satyanarayana Raju Bhupathiraju, Whole Time Director & CFO. These revisions are pending shareholder approval.

Financial Performance

Vineet Laboratories reported its financial results for the quarter and half-year ended September 30, 2025:

Particulars (in Rs. Lakhs)	Q2 FY2026	Q1 FY2026	H1 FY2026
Revenue from Operations	1741.95	744.18	2486.13
Total Income	1742.79	745.98	2488.78
Total Expenses	1705.63	836.14	2541.77
Profit/(Loss) Before Tax	37.16	(90.16)	(53.00)
Profit/(Loss) for the Period	40.10	(86.61)	(46.51)

Key financial highlights:

The company's revenue from operations in Q2 FY2026 showed a significant increase to Rs. 1741.95 lakhs, compared to Rs. 744.18 lakhs in the previous quarter.
Despite the revenue growth, Vineet Laboratories reported a net loss of Rs. 46.51 lakhs for the half-year period.
The total income for the half-year stood at Rs. 2488.78 lakhs against total expenses of Rs. 2541.77 lakhs.

Balance Sheet Overview

As of September 30, 2025:

Total assets stood at Rs. 9064.49 lakhs, slightly down from Rs. 9454.01 lakhs as of March 31, 2025.
The company's equity share capital remained unchanged at Rs. 921.90 lakhs.
Current liabilities decreased to Rs. 6790.40 lakhs from Rs. 7438.89 lakhs at the end of the previous fiscal year.

The company continues to operate in the Active Pharmaceutical Ingredients and Intermediates segment, with no changes reported in its business operations.

Vineet Laboratories' management and auditors have prepared these financial results in accordance with Indian Accounting Standards (Ind AS) and applicable regulations. The statutory auditors have issued an unqualified review report for the quarter and half-year ended September 30, 2025.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+3.16%	-1.01%	+16.09%	+63.52%	-21.49%	-0.37%

Four promoters of Vineet Laboratories Limited have significantly reduced their stakes in the company through on-market sales on September 1, 2025. The transactions, totaling ₹53.2 lakh, were conducted on the National Stock Exchange (NSE).

Details of the Share Sales

Promoter	Shares Sold	Sale Value	Stake Reduction
Satyanarayana Raju Bhupathiraju	24,213	₹8.32 lakh	2.60% to 2.34%
Alluri Prabhakar Raju	25,000	₹8.60 lakh	2.05% to 1.78%
Gaddam Venkata Ramana	80,000	₹27.51 lakh	9.01% to 8.14%
Alluri Srinivasa Raju	25,000	₹8.60 lakh	1.68% to 1.41%

Regulatory Compliance

The company has duly informed the stock exchanges about these transactions in compliance with Regulation 7(2) of SEBI (Prohibition of Insider Trading) Regulations, 2015. The disclosure was made through Form C, which was enclosed with the company's letter to the stock exchanges.

Impact on Shareholding

These sales have resulted in a cumulative reduction of promoter shareholding in Vineet Laboratories Limited. The largest sale in terms of volume and value was made by Gaddam Venkata Ramana, who offloaded 80,000 shares.

Company Background

Vineet Laboratories Limited, with its registered office in Hyderabad, Telangana, is engaged in the pharmaceutical sector. The company's shares are listed on both the BSE and NSE.